Table 2.
Sample and treatment characteristics
| Imatinib (n = 70) | Sunitinib (n = 27) | Pazopanib (n = 12) | |
|---|---|---|---|
| Male sex, n (%) | 36 (51) | 23 (85) | 8 (75) |
| Age, median (range) | 63 (8–94) | 62 (26–77) | 62 (29–74) |
| Drug levels samples, n | 290 | 75 | 31 |
| Number of drug levels per patient, median (range) | 3 (2–13) | 2 (2–8) | 3 (2–3) |
| Indication, n | GIST: 68 | mRCC: 23 | mRCC: 8 |
| ALL: 1 | GIST: 4 | STS: 4 | |
| CML: 1 | |||
| Treatment goal, n (%) | Palliative: 47 (67) | NR | NR |
| Adjuvant: 19 (27) | |||
| Neoadjuvant: 4 (6) | |||
| Mutation in GIST | cKIT exon 11: 41 | ||
| cKIT exon 9: 4 | |||
| cKIT exon 17: 1 | |||
| BCR‐ABL: 1 | |||
| PDGFRA exon 18: 6 | |||
| PDGFRA exon 12: 1 | |||
| unknown: 16 |
GIST: gastrointestinal stromal tumour; ALL: acute lymphoblastic leukaemia; CML: chronic myeloid leukaemia; mRCC: metastatic renal cell carcinoma; STS: soft tissue sarcoma; cKIT: proto‐oncogene cKIT; BCR‐Abl: fusion gene of breakpoint cluster region gene and Abelson murine leukaemia viral oncogene; PDGFRA: platelet‐derived growth factor receptor‐α; NR: not relevant for therapeutic drug monitoring.